Pelagos Insurance Capital Limited heads into the back half of 2026 with analysts nudging their price targets higher — and the stock trading just a few cents below where the Street thinks it belongs.
Three separate analyst actions landed this week, all in the same direction. UBS raised its target to $29 from $28, maintaining a Buy. Keefe, Bruyette & Woods made the identical move, keeping its Outperform intact. Barclays was more cautious on rating but still lifted its Equal-Weight target to $24 from $22. The collective message is constructive: no firm cut, every firm raised. The mean consensus target now sits at $24.61, barely above the current price of $24.48 — a gap of about $0.13 — which frames the near-term as one of execution rather than re-rating. Bulls at UBS and KBW see $29 as fair value, implying roughly 18% upside. JPMorgan remains the outlier, holding an Underweight with a $23 target, placing the stock already above what the most bearish voice on the Street considers appropriate.
The stock itself has done most of the work. PLGO is up 12.2% over the past month and about half a percent on the week, closing at $24.48 on Tuesday. That run has been broad-based across the insurance sector — closest peers CNA and gained 5.8% and 4.3% respectively on the week, while added 4.6%. PLGO lagged slightly in the weekly race, but the month's gain compares favorably across the cohort. Valuation multiples reflect the re-rating: the P/E has expanded by about 0.21 points over 30 days to 6.2x, and price-to-book moved up to 0.77x. Both remain deeply modest for an insurance name, which forms the core of the bull case.
Positioning gives little friction to the upside move. Short interest is low at 1.75% of free float and has been declining — down 8.6% on the week and about 4.4% on the month. The borrow market is exceptionally loose, with availability at 1,376%, meaning shares to lend dwarf the shares already borrowed by a wide margin. The cost to borrow has dropped sharply, nearly halving over the week to 0.21% — among the lowest readings in the 30-day window. There is no meaningful short-side pressure here; this is a stock where bears have been quietly trimming, not adding.
The ORTEX short score of 40 sits in a middle range and has been easing gradually from a recent high near 43 on June 26. Factor scores tell a mixed story. The EPS surprise rank is in the 91st percentile — the company has consistently beaten estimates — and the 90-day EPS momentum rank is a strong 85. Shorter-term 30-day EPS momentum is weak at the 16th percentile, suggesting near-term estimate revisions have softened. The dividend score of 75 adds a modest yield angle; DPS/Price runs at 2.7% on current numbers. Quality metrics have been under pressure, as flagged in prior notes — a $150 million reserve charge tied to aviation losses and California wildfire costs weighed on H1 results — but the reserve picture appears to be stabilizing, which underpins the recent analyst confidence.
On the ownership side, the top holder Crestview Advisors holds 16.7% of shares and made no change last quarter. Omega Advisors added 976,000 shares in the March period, building its 9.3% stake. BlackRock and Dimensional both added modestly through May and June respectively. Insider activity was thin — a single C-level sell of $62,000 worth in early June, too small to read as a signal. Institutional ownership is concentrated and appears stable.
The next earnings date is August 13. Given a history of sharp reactions — the May print generated a 15.3% one-day move — how the company characterizes its aviation reserve situation and any updated catastrophe loss guidance will determine whether the current analyst optimism holds or gets tested.
See the live data behind this article on ORTEX.
Open PLGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
